Medical therapy. Management of the refractory patient
- PMID: 10695005
- DOI: 10.1016/s0889-8553(05)70093-5
Medical therapy. Management of the refractory patient
Abstract
Although relatively rare, GERD patients refractory to medical therapy remain a challenge for the clinician. Refractoriness can be diagnosed only if the patient is properly studied on medication and if what should be adequate medical therapy has been given a sufficient therapeutic trial. Use of 24-hour intragastric and intraesophageal pH-metry has improved the ability to manage patients who appear to be nonresponders. Simple advice and minor adjustments to medical therapy are usually all that is needed for most patients, but in some, management requires knowledge of the principles outlined in this article. If followed, only a small group of patients should be medically refractory.
Similar articles
-
Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood.Dig Liver Dis. 2000 Nov;32(8):660-6. doi: 10.1016/s1590-8658(00)80326-6. Dig Liver Dis. 2000. PMID: 11142573 Clinical Trial.
-
Chronic cough and gastroesophageal reflux disease: experience with specific therapy for diagnosis and treatment.Chest. 2003 Mar;123(3):679-84. doi: 10.1378/chest.123.3.679. Chest. 2003. PMID: 12628862
-
Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease.Scand J Gastroenterol. 1998 Dec;33(12):1239-43. doi: 10.1080/00365529850172304. Scand J Gastroenterol. 1998. PMID: 9930385 Clinical Trial.
-
Therapeutic choices in reflux disease: defining the criteria for selecting a proton pump inhibitor.Am J Med. 2004 Sep 6;117 Suppl 5A:14S-22S. doi: 10.1016/j.amjmed.2004.07.020. Am J Med. 2004. PMID: 15478848 Review.
-
[Use of proton pump inhibitors in the treatment of gastroesophageal reflux disease].Klin Med (Mosk). 2003;81(9):54-9. Klin Med (Mosk). 2003. PMID: 14598594 Review. Russian.
Cited by
-
The pharmacology and clinical relevance of proton pump inhibitors.Curr Gastroenterol Rep. 2002 Dec;4(6):459-62. doi: 10.1007/s11894-002-0021-3. Curr Gastroenterol Rep. 2002. PMID: 12441035 Review.
-
Effect of CYP2C19 genotypes on the pharmacokinetic/pharmacodynamic relationship of rabeprazole after a single oral dose in healthy Chinese volunteers.Eur J Clin Pharmacol. 2010 Nov;66(11):1165-9. doi: 10.1007/s00228-010-0892-4. Epub 2010 Sep 14. Eur J Clin Pharmacol. 2010. PMID: 20838991 Clinical Trial.
-
Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese.Eur J Clin Pharmacol. 2014 Sep;70(9):1073-8. doi: 10.1007/s00228-014-1713-y. Epub 2014 Jul 6. Eur J Clin Pharmacol. 2014. PMID: 24996380 Clinical Trial.
-
Practical approaches to dysphagia caused by esophageal motor disorders.Curr Gastroenterol Rep. 2001 Jun;3(3):191-9. doi: 10.1007/s11894-001-0021-8. Curr Gastroenterol Rep. 2001. PMID: 11353554 Review.
-
Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole.BMC Pharmacol Toxicol. 2020 Jul 25;21(1):54. doi: 10.1186/s40360-020-00433-2. BMC Pharmacol Toxicol. 2020. PMID: 32711578 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical